This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Isis Pharmaceuticals (ISIS)

NASDAQ: Health Care

Company Balance Sheet
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Assets
Cash and Equivalents 159.97M 124.48M 65.48M 70.05M
Receivables 11.10M 522.00K 6.92M 1.24M
Inventories 8.03M 6.12M 4.14M 2.48M
Other Current Assets 59.61M 42.35M 5.42M 7.06M
Total Current Assets 735.51M 423.44M 360.14M 483.14M
Property, Plant & Equipment, Gross 146.63M 145.55M 144.04M 76.53M
Accumulated Depreciation & Depletion 60.43M 54.46M 47.42M 40.83M
Property, Plant & Equipment, Net 86.20M 91.08M 96.62M 35.70M
Intangibles 15.52M 18.65M 16.26M 15.82M
Other Non-Current Assets 9.93M 12.52M 11.88M 15.82M
Total Non-Current Assets 111.65M 122.25M 124.76M 67.34M
Liabilities & Shareholder Equity
Total Assets 847.16M 545.69M 484.89M 550.48M
Accounts Payable 11.01M 10.24M 8.30M 6.52M
Short Term Debt 4.41M 4.88M 3.39M 5.64M
Other Current Liabilities 0.00 0.00 0.00 0.00
Total Current Liabilities 97.81M 74.32M 76.11M 105.89M
Long Term Debt 77.83M 77.95M 215.45M 148.76M
Deferred Income Taxes 0.00 0.00 0.00 0.00
Other Non-Current Liabilities 293.12M 210.65M 21.90M 51.28M
Minority Interest 0.00 0.00 0.00 0.00
Total Non-Current Liabilities 370.95M 288.60M 237.35M 200.04M
Total Liabilities 468.77M 362.92M 313.46M 305.94M
Preferred Stock Equity 0.00 0.00 0.00 0.00
Common Stock Equity 378.39M 182.77M 171.43M 244.54M
Common Par 116.00K 102.00K 100.00K 99.00K
Additional Paid In Capital 1.32B 1.08B 1.01B 1.00B
Cumulative Translation Adjustment 0.00 0.00 0.00 0.00
Retained Earnings -967.61M -906.97M -841.49M -756.69M
Treasury Stock 0.00 0.00 0.00 0.00
Other Equity Adjustments 21.08M 12.48M -770.00K 949.00K
Total Capitalization 456.22M 260.72M 386.88M 393.30M
Total Equity 378.39M 182.77M 171.43M 244.54M
Total Liabilities & Stock Equity 847.16M 545.69M 484.89M 550.48M
Total Common Shares Outstanding 116.47M 101.48M 100.04M 99.39M
Preferred Shares 0.00 0.00 0.00 0.00
Treasury Shares 0.00 0.00 0.00 0.00
Basic Weighted Shares Outstanding 110.50M 100.58M 99.66M 99.14M
Diluted Weighted Shares Outstanding 110.50M 100.58M 99.66M 99.14M
Number of Employees 365 342 337 270
Number of Part-Time Employees 0 0 0 0
ISIS News

ISIS Isis Pharmaceuticals

Analysts Ratings for ISIS

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 3 3 3 3
Moderate Buy 1 1 1 1
Hold 2 2 2 2
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
GET ISIS ANALYST REPORT

Brokerage Partners

ISIS Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs